KZIA revenueFY2025A$42.0K
- FY YoY
- -98.2%
KZIA revenue was A$42.0K for fiscal 2025 (ended Jun 30, 2025), down 98.2% from fiscal 2024.
Kazia Therapeutics Limited (KZIA) financials
For fiscal 2025 (ended Jun 30, 2025), Kazia Therapeutics Limited reported A$42.0K of revenue and -A$20.70M of net income. Figures are in AUD, the currency of its SEC filings.
- Revenue, FY2025
- A$42.0K
- Revenue growth, YoY
- -98.2%
- Net income, FY2025
- -A$20.70M
- Net margin
- -49290.5%
- EPS, diluted, FY2025
- -A$0.04
- Cash
- A$4.34M
FY2016FY2025
FY2016FY2025
FY2016FY2017
KZIA revenue and earnings growth
KZIA net incomeFY2025-A$20.70M
KZIA net income was -A$20.70M for fiscal 2025 (ended Jun 30, 2025), compared with -A$26.78M in fiscal 2024.
KZIA EPSFY2025-A$0.04
KZIA diluted EPS was -A$0.04 for fiscal 2025 (ended Jun 30, 2025).
Income statement
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$42.0K | A$2.31M | A$0 | A$0 | A$15.18M | - | - | A$119.0K | A$249.0K | A$406.0K |
| Research and development | A$7.33M | A$17.38M | A$15.56M | A$20.17M | A$14.54M | A$9.49M | A$6.47M | A$9.77M | A$11.14M | A$9.89M |
| Selling, general and admin | A$8.72M | A$13.56M | A$8.58M | A$5.11M | A$7.02M | A$3.69M | A$3.79M | A$5.60M | A$8.53M | A$5.76M |
| Interest expense | - | - | - | - | - | - | - | A$0 | A$1.0K | A$0 |
| Pre-tax income | -A$22.45M | -A$27.05M | -A$20.74M | -A$25.38M | -A$8.90M | -A$12.77M | -A$10.57M | -A$6.34M | -A$10.87M | -A$12.15M |
| Income tax | -A$1.75M | -A$271.0K | -A$271.0K | -A$368.0K | -A$484.0K | -A$298.0K | -A$298.0K | -A$305.0K | -A$199.0K | - |
| Net income | -A$20.70M | -A$26.78M | -A$20.46M | -A$25.01M | -A$8.42M | -A$12.47M | -A$10.27M | -A$6.04M | -A$10.67M | -A$12.06M |
| EPS, basic | -A$0.04 | -A$0.10 | -A$0.11 | -A$0.19 | -A$0.07 | -A$0.17 | -A$17.86 | -A$12.48 | -A$2.28 | -A$2.82 |
| EPS, diluted | -A$0.04 | -A$0.10 | -A$0.11 | -A$0.19 | -A$0.07 | -A$0.17 | -A$17.86 | -A$12.48 | -A$2.28 | -A$2.82 |
| Diluted shares | 547.9M | 263.7M | 184.3M | 132.5M | 117.7M | 73.1M | 57.5M | 48.4M | 467.8M | 427.4M |
Balance sheet
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | A$4.34M | A$1.66M | A$5.24M | A$7.36M | A$27.59M | A$8.76M | A$5.43M | A$5.96M | A$14.46M | A$33.45M |
| Receivables | A$98.0K | A$3.90M | A$3.90M | A$91.0K | A$84.0K | A$1.35M | A$1.71M | A$2.54M | A$4.26M | - |
| Current assets | A$4.93M | A$6.14M | A$10.77M | A$9.45M | A$29.39M | A$10.65M | A$7.51M | A$9.26M | A$19.48M | - |
| Total assets | A$6.06M | A$21.59M | A$28.08M | A$35.89M | A$58.09M | A$23.06M | A$21.18M | A$28.18M | A$35.91M | - |
| Current liabilities | A$14.05M | A$25.80M | A$7.57M | A$6.73M | A$8.33M | A$5.07M | A$1.90M | A$3.89M | A$5.38M | - |
| Total liabilities | A$14.36M | A$31.60M | A$16.03M | A$17.61M | A$20.24M | A$8.94M | A$6.98M | A$8.93M | A$10.57M | - |
| Shareholders' equity | -A$8.30M | -A$10.02M | A$12.05M | A$18.27M | A$37.85M | A$14.13M | A$14.20M | A$19.24M | A$25.34M | A$33.93M |
Cash flow
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -A$13.28M | -A$9.58M | -A$15.16M | -A$22.76M | -A$9.11M | -A$8.81M | -A$6.71M | -A$8.66M | -A$11.44M | -A$11.98M |
| Capital expenditures | - | - | - | - | - | - | - | - | A$12.0K | A$522.0K |
| Free cash flow | - | - | - | - | - | - | - | - | -A$11.45M | -A$12.50M |
| Investing cash flow | - | A$0 | A$0 | -A$2.37M | - | - | A$2.36M | A$150.0K | -A$7.12M | -A$522.0K |
| Financing cash flow | A$15.98M | A$5.99M | A$12.97M | A$3.73M | A$28.11M | A$12.14M | A$3.82M | - | -A$18.0K | A$782.0K |
| Stock-based compensation | A$653.0K | A$533.0K | A$1.16M | A$1.68M | A$637.0K | A$262.0K | A$246.0K | A$165.0K | A$517.0K | A$372.0K |
| Depreciation and amortization | - | - | A$1.87M | A$1.87M | A$1.26M | A$1.08M | A$1.08M | A$1.55M | A$1.42M | A$643.0K |
Key ratios
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -98.2% | - | - | -100.0% | - | - | - | -52.2% | -38.7% | - |
| Net margin | -49290.5% | -1160.2% | - | - | -55.5% | - | - | -5074.8% | -4285.1% | -2971.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -4597.2% | -3079.3% |
| Return on equity | - | - | -169.8% | -136.9% | -22.2% | -88.3% | -72.3% | -31.4% | -42.1% | -35.6% |
| Return on assets | -341.6% | -124.1% | -72.9% | -69.7% | -14.5% | -54.1% | -48.5% | -21.4% | -29.7% | - |
| Current ratio | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.96 | 2.38 | 3.62 | - |
Source: XBRL data Kazia Therapeutics Limited files with the SEC, latest filing dated Nov 7, 2025 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
KZIA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KZIA | A$42.0K | -98.2% | -A$20.70M | -49290.5% | $115.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
KZIA FAQ
7 questionsWhat is KZIA revenue?
Kazia Therapeutics Limited (KZIA) reported A$42.0K of revenue for fiscal 2025 (ended Jun 30, 2025). That is down 98.2% from the year before.Is KZIA profitable?
No. Kazia Therapeutics Limited reported a net loss of A$20.70M for fiscal 2025 (ended Jun 30, 2025).How much cash and debt does KZIA have?
Kazia Therapeutics Limited reported A$4.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is KZIA revenue growing?
Kazia Therapeutics Limited's revenue changed -98.2% in fiscal 2025, to A$42.0K.What is KZIA earnings per share?
Diluted earnings per share were -A$0.04 for fiscal 2025 (ended Jun 30, 2025), from SEC filings, restated for any stock split those filings show.When did KZIA last report financial results?
The latest statements here come from Kazia Therapeutics Limited's 20-F filed on Nov 7, 2025, covering the period ended Jun 30, 2025.Where does this KZIA financial data come from?
Quantisnow builds these statements from the structured XBRL data Kazia Therapeutics Limited files with the SEC. It is provided for information only and is not investment advice.